Organ engineering – VJRegenMed

Advances in organ bioengineering

admin_vjr_user — Tue, 04 Jan 2022 17:52:19 +0000

Paolo De Coppi, MD, PhD, FMedSci, UCL Great Ormond Street Institute of Child Health & NIHR Biomedical Research Centre, London, UK, provides an overview of the current landscape of bioengineering for organ replacement and some of the key considerations during the development of tissue-engineered organs, including the types of cell and polymers used. He notes that for the regeneration of simple tissues, autologous somatic cells may be sufficient, however, for more complex organs, pluripotent stem cells would likely be required, which would require immunosuppression upon implantation in order to avoid tissue rejection. Dr De Coppi also describes ongoing research into the use of biliary organoids for the repair of the damaged liver. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

Driving the translation of intestinal tissue engineering

admin_vjr_user — Tue, 04 Jan 2022 17:52:17 +0000

Paolo De Coppi, MD, PhD, FMedSci, UCL Great Ormond Street Institute of Child Health & NIHR Biomedical Research Centre, London, UK, describes ongoing research aiming to address challenges facing the development of tissue engineering strategies for the treatment of intestinal failure and their translation into patients. While it has been demonstrated that organoid technology can used to replace the intestinal mucosa, the development of Good Manufacturing Practice (GMP)-compliant methods for organoid expansion are required before human transplantation. Given the organ complexity of the intestine, instead of engineering the entire intestine, ongoing research is focused on engineering a functional small intestine mucosa which could be transplanted into the large intestine. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

Advancements in organ engineering

Simon Ng — Tue, 30 Nov 2021 18:07:19 +0000

Giuseppe Orlando, MD, PhD, Wake Forest School of Medicine, Winston-Salem, NC, discusses current developments in organ engineering. Healthy mitochondria can repair damaged kidneys, and decellularization can enable procurement of biomaterials that can regenerate islet cells in the pancreas, or help stem cells differentiate into β cells. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

The future of regenerative medicine in transplantation

Simon Ng — Tue, 30 Nov 2021 18:07:16 +0000

Giuseppe Orlando, MD, PhD, Wake Forest School of Medicine, Winston-Salem, NC, describes recent advances in the field of transplantation, including the development of β cell replacement therapies for Type 1 diabetes. Prof. Orlando additionally discusses novel organ preservation techniques which utilizes fluids that store organs at room temperature instead of ice, as well as the use of mesenchymal stem cells and mitochondria to render once unusable organs suitable for transplantable. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Bio-engineering vascularized islet organs for T1D

Simon Ng — Tue, 30 Nov 2021 18:07:14 +0000

Lorenzo Piemonti, MD, Università Vita-Salute San Raffaele, Milan, Italy, describes advancements in the field of β cell replacement in Type 1 diabetes. Translation of β cells from an in vitro to in vivo environment has been a major hurdle, due to the loss of cell mass during engraftment and immunogenicity. Ex vivo vascularized islet organs (VIOs) aims to overcome these issues, and consist of an engraftable decellularized lung scaffold containing endocrine cells. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Next steps for procine-derived bioengineered organs

Simon Ng — Thu, 25 Nov 2021 18:05:25 +0000

Jeff Ross, PhD, Miromatrix, Eden Prairie, MN, describes the process of taking bioengineered organs derived from porcine organs to clinical trials. The porcine organ scaffold produced as a result of perfusion decellularization has been successfully commercialized and is currently used in transplants Published studies have additionally shown the process of perfusion recellularization to be successful in creating viable bioengineered organs. This interview took place at Meeting on the Mesa 2021.

Can manufacturing bioengineered organs be scaled up?

Simon Ng — Thu, 25 Nov 2021 18:05:23 +0000

Jeff Ross, PhD, Miromatrix, Eden Prairie, MN, discusses the manufacturability of bioengineered organs developed from porcine organs. Dr Ross highlights how the decellularized porcine cells leaves behind an extracellular matrix and that the scaffold has already been commercialized. The current techniques to mass produce bioengineered organs can subsequently be scaled up by using bioreactors. This interview took place at Meeting on the Mesa 2021.

Innovative regulatory pathways for next-generation treatments

Simon Ng — Thu, 11 Nov 2021 10:21:29 +0000

Jeff Ross, PhD, Miromatrix, Eden Prairie, MN, provides a brief overview of the topics discussed at the “Innovative regulatory pathways for next-generation treatments” session at Meeting on the Mesa 2021. Novel products and technologies result in unique regulatory pathways and Dr Ross describes his experiences with regulatory authorities. He additionally highlights INTERACT meetings with the FDA, which enables companies to receive guidance on the development of their products. This interview took place at Meeting on the Mesa 2021.

Developing bioengineered organs of porcine origin

Simon Ng — Thu, 11 Nov 2021 10:21:28 +0000

Jeff Ross, PhD, Miromatrix, Eden Prairie, MN, describes the process of creating transplantable human organs from porcine organs. Harvested porcine organs initially undergo perfusion decellularization, which strips the porcine cells away, leaving a extracellular matrix and vascular network. The organ is then repopulated with human cells in a process known as perfusion recellularization, which additionally provides organ functionality. This interview took place at Meeting on the Mesa 2021.

Addressing the need for bioengineered organs

Simon Ng — Thu, 11 Nov 2021 10:21:27 +0000

Jeff Ross, PhD, Miromatrix, Eden Prairie, MN, highlights the need for transplantable bioengineered livers and kidneys. Patients with liver failure face long waits for transplantation and there are no treatment options nor medical devices available, exacerbating the demand for alternatives to liver donations. Whilst dialysis is an option for patients with kidney failure, a poorer quality of life and long-term mortality means that bioengineered kidneys will be a suitable alternative. Dr Ross additionally mentions the potential for the technology to be expanded to other organs including the lungs, heart and pancreas. This interview took place at Meeting on the Mesa 2021.